With 1.2 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.99 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.244 whereas the lowest price it dropped to was $0.23. The 52-week range on CLRB shows that it touched its highest point at $3.49 and its lowest point at $0.22 during that stretch. It currently has a 1-year price target of $3.00. Beta for the stock currently stands at 0.49.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CLRB was down-trending over the past week, with a drop of -1.43%, but this was down by -18.27% over a month. Three-month performance dropped to -16.25% while six-month performance fell -88.65%. The stock lost -92.16% in the past year, while it has lost -19.50% so far this year. A look at the trailing 12-month EPS for CLRB yields -0.75 with Next year EPS estimates of -0.66. For the next quarter, that number is -0.14. This implies an EPS growth rate of 50.82% for this year and -9.44% for next year. EPS is expected to grow by 17.97% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 40.27%.
Float and Shares Shorts:
At present, 46.08 million CLRB shares are outstanding with a float of 45.31 million shares on hand for trading. On 2025-04-30, short shares totaled 1.56 million, which was 339.0 higher than short shares on 1743379200. In addition to Mr. James V. Caruso as the firm’s President, CEO & Director, Mr. Chad J. Kolean CPA serves as its VP, CFO & Secretary.
Institutional Ownership:
Through their ownership of 0.12783 of CLRB’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, CLRB reported revenue of $0.0 and operating income of -$12744826.0. The EBITDA in the recently reported quarter was -$22887498.0 and diluted EPS was $nan.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CLRB since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With CLRB analysts setting a high price target of 13.0 and a low target of 3.0, the average target price over the next 12 months is 8.0. Based on these targets, CLRB could surge 5316.67% to reach the target high and rise by 1150.0% to reach the target low. Reaching the average price target will result in a growth of 3233.33% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$1.47459 being high and -$1.7398 being low. For CLRB, this leads to a yearly average estimate of -$1.6125.
